Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INEX Innovate
Singapore, Singaporeinexinnovate.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
INEX Innovate has commercialized several proprietary molecular diagnostic tests for women’s health, including intra-operative and point-of-care ovarian cancer diagnostics (OvaCis), prenatal genetic testing (iGene NIPT), and breast cancer liquid biopsy (EpiDx); its tests are well-validated and used across Asia, with ongoing clinical validation for additional technologies
- Therapeutic areas
- Women's HealthOncologyRare Diseases
- Modalities
- Diagnostic testMolecular diagnosticsLiquid biopsyNext generation sequencing-based diagnostic
- Industry
- Molecular Diagnostics
02
Partnerships
Malaysian conglomerate Genting Berhad (investor/backer/board)Enterprise Singapore (government funding)SNS Holdings (investment firm)Collaborations with National University of Singapore (start-up origins)
Beyond the preview
Go deeper on INEX Innovate.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INEX Innovate.